Small-molecular targeting of drugs in breast cancer treatment
Breast cancer is the most common malignant neoplasm in women, and its treatment is constantly being updated, in which the application of small molecular targets to medications gives new hope to breast cancer patients. Small molecular target drugs have the following advantages compared to traditional chemotherapy:
I. Precision and efficacy
The mechanism of small molecular target-to-pharmaceutical action is to inhibit the growth, growth and spread of tumour cells by combining them with the target points on tumour cells. This method of precision strikes makes the target drug more effective in treating breast cancer. For example, a single drug (Hessetine) that targets Sher2 positive breast cancer can significantly increase the survival rate of Her2 positive breast cancer patients.
II. Low side effects and patient tolerance
While killing tumour cells, traditional chemotherapy can cause damage to normal cells, leading to a range of side effects such as nausea, vomiting, hair loss, bone marrow suppression, etc. The side effects of small molecular target drugs are relatively low because of their high selectivity and the small damage to normal cells. This enables the patient to maintain a better quality of life during the treatment process and improves the dependence of the treatment.
III. Targeted and adapted
The development of small molecular target-to-pharmaceuticals is usually directed at specific gene mutation or protein expression anomalies. In breast cancer treatment, the patient can choose the appropriate target for the drug based on his or her genetic test results. For example, for breast cancer patients with an increase in the HeR2 gene, it is possible to use a single antichorus; for patients with HIV positive/HER2 negative breast cancer, it is possible to use a CDK4/6 inhibitor such as Paposini (Patet). This individualized treatment makes the target drug more relevant for breast cancer treatment.
IV. Joint treatment to improve efficacy
Small molecular targets can be used in combination with other treatments, such as chemotherapy and endocrine treatment, to create synergies and improve treatment effectiveness. For example, the programme of treatment of tratophoto-synthetics alone can significantly improve the non-sick life and total survival of persons with positive breast cancer at Her2.
V. Rapid progress and prospects for research
As molecular biology continues to develop, an increasing number of breast cancer-related molecular targets are being found, and there is a continuing breakthrough in the development of small molecular targets for these targets. At present, there are a number of small-molecule targets that show good efficacy in the clinical application of drugs, and it is hoped that in the future, more breast cancer patients will be evangelized.
Despite the many advantages of small molecular target drugs in breast cancer treatment, not all patients are fit for use. Patients are required to undergo genetic tests before being used to determine if there is a corresponding mutation of target. In addition, drug resistance problems may arise in target-oriented drug use, requiring timely adjustment of treatment programmes.
In general, small-molecule targets provide patients with more accurate, efficient and less intrusive treatment options for the use of drugs in breast cancer treatment. As research continues, it is believed that, in the future, small molecular target drugs will play a greater role in breast cancer treatment, providing better treatment and quality of life for patients.
